Patient and disease characteristics at baseline
| Characteristic . | Patients with a confirmed diagnosis . | All enrolled patients (n = 260) . | ||
|---|---|---|---|---|
| Total (n = 229) . | Previously untreated (n = 148) . | Previously treated (n = 81) . | ||
| Median age, y (range) | 56 (19-81) | 57 (19-81) | 52 (20-73) | 56 (19-81) |
| Sex: M/F | 128/101 | 81/67 | 47/34 | 136/124 |
| ECOG score (no. [%] of patients) | ||||
| 0-1 | 135 (59) | 90 (61) | 45 (56) | 150 (58) |
| 2 | 85 (37) | 52 (35) | 33 (41) | 97 (37) |
| 3 | 2 (1) | 1 (1) | 1 (1) | 4 (2) |
| Median y since initial diagnosis of CML (25th-75th percentile) | 3.4 (1.4-5.8) | 3.1 (1.2-6.0) | 3.5 (1.7-5.7) | 3.4 (1.5-5.8) |
| Median mo since diagnosis of blast crisis (25th-75th percentile) | 0.6 (0.2-2.3) | 0.4 (0.2-0.9) | 2.8 (0.8-5.6) | 0.6 (0.3-2.5) |
| Extramedullary involvement (no. [%] of patients) | 160 (70) | 108 (73) | 52 (64) | 179 (69) |
| Splenomegaly ≥ 10 cm below costal margin | 61 (27) | 42 (28) | 19 (23) | 65 (25) |
| Lymph node | 24 (10) | 20 (14) | 4 (5) | 24 (9) |
| Other (chloroma) | 7 (3) | 4 (3) | 3 (4) | 7 (3) |
| Median hemoglobin, g/L (25th-75th percentile) | 93 (85-104) | 94 (86-107) | 92 (85-99) | 92 (85-103) |
| Median WBC count, × 109/L (25th-75th percentile) | 31 (13-67) | 27 (11-56) | 42 (13-80) | 29 (10-66) |
| Median platelet count, × 109/L (25th-75th percentile) | 66 (29-194) | 80 (30-204) | 63 (28-168) | 75 (29-208) |
| Median blasts in bone marrow, % (25th-75th percentile) | 50 (35-70) | 48 (33-70) | 57 (39-71) | 46 (32-70) |
| Median blasts in peripheral blood, % (25th-75th percentile) | 35 (13-61) | 34 (11-57) | 37 (14-68) | 30 (10-56) |
| Initial dose of imatinib (no. [%] of patients) | ||||
| 400 mg | 32 (14) | 10 (7) | 22 (27) | 37 (14) |
| 600 mg | 197 (86) | 138 (93) | 59 (73) | 223 (86) |
| Characteristic . | Patients with a confirmed diagnosis . | All enrolled patients (n = 260) . | ||
|---|---|---|---|---|
| Total (n = 229) . | Previously untreated (n = 148) . | Previously treated (n = 81) . | ||
| Median age, y (range) | 56 (19-81) | 57 (19-81) | 52 (20-73) | 56 (19-81) |
| Sex: M/F | 128/101 | 81/67 | 47/34 | 136/124 |
| ECOG score (no. [%] of patients) | ||||
| 0-1 | 135 (59) | 90 (61) | 45 (56) | 150 (58) |
| 2 | 85 (37) | 52 (35) | 33 (41) | 97 (37) |
| 3 | 2 (1) | 1 (1) | 1 (1) | 4 (2) |
| Median y since initial diagnosis of CML (25th-75th percentile) | 3.4 (1.4-5.8) | 3.1 (1.2-6.0) | 3.5 (1.7-5.7) | 3.4 (1.5-5.8) |
| Median mo since diagnosis of blast crisis (25th-75th percentile) | 0.6 (0.2-2.3) | 0.4 (0.2-0.9) | 2.8 (0.8-5.6) | 0.6 (0.3-2.5) |
| Extramedullary involvement (no. [%] of patients) | 160 (70) | 108 (73) | 52 (64) | 179 (69) |
| Splenomegaly ≥ 10 cm below costal margin | 61 (27) | 42 (28) | 19 (23) | 65 (25) |
| Lymph node | 24 (10) | 20 (14) | 4 (5) | 24 (9) |
| Other (chloroma) | 7 (3) | 4 (3) | 3 (4) | 7 (3) |
| Median hemoglobin, g/L (25th-75th percentile) | 93 (85-104) | 94 (86-107) | 92 (85-99) | 92 (85-103) |
| Median WBC count, × 109/L (25th-75th percentile) | 31 (13-67) | 27 (11-56) | 42 (13-80) | 29 (10-66) |
| Median platelet count, × 109/L (25th-75th percentile) | 66 (29-194) | 80 (30-204) | 63 (28-168) | 75 (29-208) |
| Median blasts in bone marrow, % (25th-75th percentile) | 50 (35-70) | 48 (33-70) | 57 (39-71) | 46 (32-70) |
| Median blasts in peripheral blood, % (25th-75th percentile) | 35 (13-61) | 34 (11-57) | 37 (14-68) | 30 (10-56) |
| Initial dose of imatinib (no. [%] of patients) | ||||
| 400 mg | 32 (14) | 10 (7) | 22 (27) | 37 (14) |
| 600 mg | 197 (86) | 138 (93) | 59 (73) | 223 (86) |
ECOG indicates Eastern Cooperative Oncology Group; CML, chronic myelogenous leukemia; and WBC, white blood cell.